Myricx Bio Announces Appointment of Paolo Paoletti MD as an Independent Non Executive Director
07 oct. 2024 04h46 HE
|
Myricx Bio
LONDON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates...
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
08 juil. 2024 02h00 HE
|
Myricx Bio
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated...
Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
27 nov. 2023 11h00 HE
|
Myricx Bio
Data published today in Nature Cell Biology by Myricx collaborators at the MRC-LMS (Laboratory of Medical Sciences) led by Prof. Jesús Gil have uncovered the central role of N-myristoyltransferase...
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
21 nov. 2023 04h00 HE
|
Myricx Bio
LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug...
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
15 nov. 2023 03h00 HE
|
Myricx Bio
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads...
Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class
17 oct. 2023 07h00 HE
|
Myricx Bio
Preclinical efficacy studies validate Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) payload platformComplete tumour regressions across a range of solid tumour xenograft models for...
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
04 oct. 2023 04h00 HE
|
Myricx Bio
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for...
Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
13 sept. 2023 04h00 HE
|
Myricx Bio
LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for...
Myricx Enters into Antibody License Agreement with Biocytogen
07 sept. 2023 07h00 HE
|
Myricx Bio
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for...
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
17 avr. 2023 13h30 HE
|
Myricx Pharma
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload...